Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Clinical Data
  • Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidate
  • Clinical Data

Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidate

BioSpace

If Biogen has shown that tau can impact cognition, Denali's technology--validated with an FDA approval in Hunter syndrome--could ensure the medicine gets where it needs to be for the greatest therapeuti

Neuroscience

Read full story

pharminent May 15, 2026

BioSpace

If Biogen has shown that tau can impact cognition, Denali’s technology–validated with an FDA approval in Hunter syndrome–could ensure the medicine gets where it needs to be for the greatest therapeuti

Neuroscience

Read full story

Post navigation

Previous: Genmab drops 2 antibody assets, including another ProfoundBio ADC
Next: ECO 2026: tirzepatide shows potential for T1D treatment

Related Stories

  • Clinical Data

Novartis hit as Lp(a) drug fails cardio outcomes trial

pharminent September 7, 2026
  • Clinical Data

Major trial of Roche Alzheimer’s drug kicks off in Europe

pharminent September 7, 2026
  • Clinical Data

AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study

pharminent September 4, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.